pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·May 8·1 min read
save

Trump reportedly plans to dismiss FDA Commissioner Marty Makary

May 8, 2026·read at Endpoints ↗RegulatoryNegative

Multiple media outlets report that President Donald Trump is considering removing FDA Commissioner Marty Makary from his post. The reports say the decision has not been finalized and could still be altered.

Makary, who leads the agency that regulates drug approvals and medical products, would be replaced if the plan proceeds, potentially affecting the FDA’s ongoing initiatives.

The story cites the Wall Street Journal among other sources, noting that the administration has not confirmed the move and that further developments are expected.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Trump plans to fire Makary from FDA role, according to reports”

read at Endpoints ↗
109 words · retrieved May 8
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Sionna Therapeutics, Inc.

related stories

  • Jun 4Hikma to funnel $267M to Ohio; Cingulate gets CRL for ADHD drugEndpoints
  • Jun 3Mineralys makes money moves before looming hypertension approvalEndpoints
  • Jun 2#ASCO26: Celcuity plans another FDA filing after positive breast cancer readoutEndpoints
  • Jun 2Praxis sinks on late-stage study fail for seizure pill, halts second trialEndpoints
  • May 29#ASCO26: Bristol Myers details Phase 3 trial win for Pomalyst successorEndpoints